Optimer Pharmaceuticals, Inc.  

(Public, NASDAQ:OPTR)   Watch this stock  
Find more results for OPTR
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -1.74
Shares 48.90M
Beta     -
Inst. own 82%

Key stats and ratios

Q2 (Jun '13) 2012
Net profit margin -133.89% -36.70%
Operating margin -135.13% -89.47%
EBITD margin - -88.60%
Return on average assets -83.98% -21.83%
Return on average equity -111.01% -26.93%
Employees 281 -
CDP Score - -


101 Hudson St Ste 3501
JERSEY CITY, NJ 07302-3915
United States - Map
+1-201-3338819 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Optimer Pharmaceuticals, Inc. (Optimer) is a biopharmaceutical company focused on developing and commercializing hospital specialty products. The Company’s development is focused on products that treat gastrointestinal infections and related diseases. Its two products OPT-822/821 and CEM-101 (OP-1068) are in clinical development. Optimer’s products include Fidaxomicin and Solithromycin under anti-infectives, and OPT-822/821 under other therapeutic areas. In January 2011, its majority owned subsidiary, Optimer Biotechnology, Inc. (OBI) conducted a Phase 2/3 clinical, trial to evaluate OPT-822/821for the treatment of metastatic breast cancer. On May 27, 2011, the United States Food and Drug Administration (FDA) approved DIFICID(fidaxomicin) tablets, its antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). In October 2013, Cubist Pharmaceuticals, Inc announced that it has completed its acquisition of Optimer Pharmaceuticals, Inc.